A Phase 1 Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Sep 2018
At a glance
- Drugs Daratumumab (Primary) ; Hyaluronidase
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 31 Aug 2018 Planned End Date changed from 12 Jul 2018 to 30 Sep 2019.
- 03 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Aug 2017 Status changed from not yet recruiting to recruiting.